Back to Search
Start Over
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
- Source :
-
Biochemical pharmacology [Biochem Pharmacol] 2020 Jul; Vol. 177, pp. 113935. Date of Electronic Publication: 2020 Mar 26. - Publication Year :
- 2020
-
Abstract
- Ketamine, an anesthetic developed in the early 1960s, is also a popular abused drug among young people at dance parties and raves and among spiritual seekers, because it produces schizophrenia-like symptoms and dissociation (i.e., out-of-body experience). Regarding mood disorders, ketamine exerts robust antidepressant actions in treatment-resistant patients with depression. Ketamine is a racemic mixture comprising equal parts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine). The United States (US) Food and Drug Administration approved the J&J (S)-ketamine nasal spray for treatment-resistant depression on March 5, 2019; the spray was then approved in Europe (December 19, 2019). Although (R)-ketamine has lower affinity for the N-methyl-d-aspartate receptor (NMDAR) vs. (S)-ketamine, (R)-ketamine has greater potency and longer-lasting antidepressant-like actions in animal models of depression. Importantly, (R)-ketamine has less detrimental side effects than does (R,S)-ketamine or (S)-ketamine in rodents, monkeys, and humans. A role for the brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB) receptor in the antidepressant effects of ketamine and its two enantiomers has been suggested. A recent RNA-sequencing analysis suggested that the transforming growth factor β1 (TGF-β1) plays a role in the antidepressant effects of (R)-ketamine. A recent pilot study demonstrated that (R)-ketamine had rapid-acting and sustained antidepressant effects in treatment-resistant patients with depression. In this article, the author reviews the mechanisms of the antidepressant actions of the enantiomers of ketamine and its metabolites, (S)-norketamine and (2R,6R)-hydroxynorketamine (HNK) and discusses the role of the brain-gut-microbiota axis and brain-spleen axis in stress-related psychiatric disorders, such as depression.<br /> (Copyright © 2020 The Author. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Antidepressive Agents therapeutic use
Brain metabolism
Brain-Derived Neurotrophic Factor metabolism
Depression drug therapy
Depression metabolism
Gastrointestinal Microbiome drug effects
Humans
Ketamine chemistry
Ketamine pharmacology
Ketamine therapeutic use
Receptors, N-Methyl-D-Aspartate metabolism
Spleen metabolism
Antidepressive Agents chemistry
Antidepressive Agents pharmacology
Ketamine analogs & derivatives
Receptors, N-Methyl-D-Aspartate antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2968
- Volume :
- 177
- Database :
- MEDLINE
- Journal :
- Biochemical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 32224141
- Full Text :
- https://doi.org/10.1016/j.bcp.2020.113935